REXTOVY

Post-LOE

naloxone hydrochloride

R-Pharm US
NDANASALSPRAY, METERED
Approved
Mar 2023
Lifecycle
Post-LOE
Competitive Pressure
35/100

Loss of Exclusivity

LOE Date
Mar 7, 2026
0 months away
Exclusivity Expiry
Mar 7, 2026
Company
R-Pharm US
R-Pharm US
NJ - Princeton
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers